Sanofi and Regeneron have been working together for years, sharing a fruitful partnership that has resulted in the development of a range of innovative treatments. Recently, the two companies signed a new agreement, aimed at further strengthening their collaboration.
The new agreement centers around Sanofi`s investment in Regeneron, which will help both companies to continue cutting-edge research in the field of immunology and inflammation. Sanofi will invest $2.5 billion, giving it a 23% stake in Regeneron, while Regeneron will use the funding to continue innovating in its core areas of focus.
This investment follows on from a long history of collaboration between Sanofi and Regeneron. The two companies have worked together on a number of high-profile projects, including the development of the cholesterol-lowering drug Praluent and the anti-inflammatory drug Kevzara. Both of these treatments have been approved for use in the US and the European Union, and have helped to improve the lives of millions of people.
By investing in Regeneron, Sanofi is helping to ensure that the partnership between the two companies remains strong. It also demonstrates Sanofi`s commitment to investing in innovative research in areas where there is a high unmet medical need.
Regeneron, for its part, will continue to focus on developing groundbreaking treatments for a range of conditions, such as cancer, eye disease, and inflammatory conditions. The company has a strong track record in these areas, and its innovative approaches to drug development have helped to improve the lives of countless patients.
Together, Sanofi and Regeneron are a powerful force in the world of biotechnology and pharmaceuticals. With this new investment, they will be able to continue to push the boundaries of innovation, and to develop treatments that have the potential to transform the lives of patients around the world.